FIELD: chemistry.
SUBSTANCE: described fused protein contains at least two amino acid sequences. The first amino acid sequence, having 90% sequence identity with an amino acid sequence represented in SEQ ID NO:2, is fused with a second amino acid sequence, having at least 90% sequence identity with an amino acid sequence represented in SEQ ID NO:4.
EFFECT: invention provides immunity against various clinically vital strains of group B streptococci.
9 cl, 5 dwg, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMMUNOGENIC FUSED PROTEIN | 2016 |
|
RU2757426C2 |
| IMMUNOGEN PEPTIDE AGAINST GROUP A STREPTOCOCCI | 2018 |
|
RU2775621C2 |
| OspA CHIMERIC GENES, PROTEINS, AND METHODS FOR THEIR USE | 2011 |
|
RU2636455C2 |
| FUSION PROTEIN | 2016 |
|
RU2748643C2 |
| OSPA CHIMERIC GENES, PROTEINS AND METHODS FOR USE THEREOF | 2011 |
|
RU2583289C2 |
| MODIFIED BIOTIN-BINDING PROTEIN, FUSION PROTEINS BASED THEREON AND THEIR APPLICATION | 2012 |
|
RU2632651C2 |
| CHIMERIC OSPA GENES, PROTEINS AND THEIR APPLICATION METHODS | 2011 |
|
RU2773402C2 |
| RECOMBINANT ATTENUATED MICROORGANISMS CLOSTRIDIUM AND VACCINE | 2007 |
|
RU2445364C2 |
| METHOD FOR CREATING RECOMBINANT ENTEROCOCCUS L3-SARSN1 STRAIN BASED ON BIOLOGICALLY ACTIVE ENTEROCOCCUS FAECIUM L3 STRAIN | 2022 |
|
RU2820058C1 |
| PREVENTIVE VACCINE AGAINST FALLOW EGG SYNDROME (EDS) | 2015 |
|
RU2720978C2 |
